Effect of Sacubitril/valsartan on natriuretic peptides – Cardiology MCQ
Effect of Sacubitril/valsartan on natriuretic peptides is:
a) Decrease in BNP and NT-proBNP
b) Increase in BNP and NT-proBNP
c) Increase in BNP and decrease in NT-proBNP
d) Decrease in BNP and increase in NT-proBNP
Correct answer: c) Increase in BNP and decrease in NT-proBNP
Both BNP and NT-proBNP are natriuretic peptides which are increased in heart failure. Angioensin receptor neprilysin inhibitor (ARNI) Sacubitril/Valsartan improves heart heart failure and thereby decreases NT-proBNP levels. But by way of neprilysin inhibition, degradation of BNP is reduced and BNP level tends to rise [1]
Reference
1. Zil...
Source: Cardiophile MD - December 8, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
New Heart Failure Drug Struggles To Find Its Footing
–Experts offer insight about Entresto at the ESC. Despite its success in a large and widely praised clinical trial the novel heart failure drug Entresto (sacubitril/valsartan, Novartis) has been struggling to gain a substantial foothold in the marketplace. Now new papers and presentations and commentary from experts at the European Society of Cardiology meeting are...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 29, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Policy & Ethics cost effectiveness Entresto LCZ 696 PARADIGM Source Type: blogs
New FDA-Approved Medication, ARNI Therapy, Could Prevent Nearly 30,000 Deaths From Heart Failure
h1, h2, h3, h4, h5, h6 { font-weight: bold; } h1 { font-size: 1.25em; line-height: 1.4em; } h2 { font-size: 1.125em; } h3 { font-size: 1.05em; } h4, h5, h6 { font-size: 1em; margin: 1em 0; } h1.title { text-align: start; -webkit-hyphens: manual; margin-bottom: 1em; } .title { display: none; } :nth-child(1 of .page) .title { display: block; } .page { text-align: start; word-wrap: break-word; } .page.rtl { direction: rtl; } a { color: rgb(65,...
Source: Dr Portnay - August 15, 2016 Category: Cardiology Authors: Dr Portnay Source Type: blogs
Entresto Gets Boost in Updated HF Guidelines
–Valsartan/sacubitril earns Class I recommendation Cardiology groups in the U.S. and Europe have updated their heart failure guidelines to include much-awaited recommendations for Entresto (the combination of valsartan and sacubitril manufactured by Novartis). The new guidelines offer broad support for the new drug. Since its approval last summer Entresto has struggled to gain a foothold...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 20, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ Source Type: blogs
Novartis Announces Enormous Clinical Trial Program For Heart Failure Drug
–The company plans to perform 40 clinical trials in 5 years with Entresto. Novartis announced today an enormous clinical trial program with its promising but slow starting heart failure drug Entresto (valsartan/sacubitril). The company said it would perform 40 clinical trials with the drug in the next five years. The Fortifying Heart Failure clinical evidence and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 19, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events clinical trials Entresto LCZ Source Type: blogs
DM / DNB Cardiology Entrance Mock Test 9
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.
If loading fails, click here to try again
Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. There is no time limit for this mock test.
Start
Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 9.
You scored %%SCORE%% out of %%TOTAL%%.
Your performan...
Source: Cardiophile MD - January 27, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
DM / DNB Cardiology Entrance Mock Test 7
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.
If loading fails, click here to try again
Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. There is no time limit for this mock test.
Start
Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 7.
You scored %%SCORE%% out of %%TOTAL%%.
Your performan...
Source: Cardiophile MD - January 23, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
Will the Pharmaceutical Industry Learn From Past Mistakes?
By SOEREN MATTKE, MD
Awash in negative headlines, public condemnation and government scrutiny, the pharmaceutical industry faces a public relations problem that, left untreated, could bring new regulations or sanctions either from governments or the courts. At the same time, though, the recent scandals over price gouging could offer an opportunity for responsible, research-based companies to distance themselves from the profiteers.
The industry has come under fire at a time of unprecedented innovation. As a physician who trained in the 1990s, I am in awe of the recent breakthroughs. Immuno-oncology drugs like Keytruda (pem...
Source: The Health Care Blog - January 22, 2016 Category: Consumer Health News Authors: Simon Nath Tags: THCB Soeren Mattke Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases.
The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Alzheimer’s disease and macular degeneration concerns with Entresto
Three academic physicians, writing in an editorial in the Journal of the American Medical Association, raised serious (but theoretical) concerns about the risk of Alzheimer’s disease and macular degeneration with long-term use of the new heart failure drug, valsartan/sacubitril (Entresto, Novartis).
Here is the translation:
Sacubitril is a drug that inhibits neprilysin, which is an enzyme (protein) responsible for breaking down things called natriuretic peptides (other proteins). This is good for heart failure patients because having more natriuretic peptides may prevent worsening heart muscle weakness. The problem i...
Source: Dr John M - January 7, 2016 Category: Cardiology Authors: Dr John Source Type: blogs
PARADIGM Investigators Estimate Entresto Prolongs Life by 1-2 Years
Treatment with Entresto (the combination of sacubitril and valsartan, formerly known as LCZ 696) instead of an ACE inhibitor will add approximately one to two years of life for most people taking the drug, according to new estimates published in the New England Journal of Medicine. Because of the time and population limitations of clinical trials it...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 2, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Prevention, Epidemiology & Outcomes Entresto LCZ 696 life expectancy long term use PARADIGM Source Type: blogs
Novartis Heart Failure Drug Gains Approval In Europe
Entresto, the novel heart failure drug from Novartis, has now been approved in Europe. The company said the drug, a twice-a-day combination of sacubitril and valsartan (formerly known as LCZ 696), had been approved by the European Commission for the treatment of people with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). The news follows previous approval of the drug by...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 24, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Entresto LCZ 696 Novartis Source Type: blogs
Slow Start For New Novartis Heart Failure Drug Entresto
Initial sales of Entresto (the combination of sacubitril and valsartan, formerly known as LCZ696) have been slow. In the first few months after its approval in July the drug only had $16 million in sales, the drug’s manufacturer, Novartis, reported last week during its quarterly earnings report. The novel heart failure drug is widely expected to be...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 2, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ 696 Medicare Novartis Source Type: blogs
What medications have you been able to stop on the Wheat Belly lifestyle?
I posed this question on the Wheat Belly Facebook page recently and received an overwhelming response. Here, I share a partial list of the responses: medications people have been able to stop by following the Wheat Belly lifestyle.
Just take a look at this incredible list: these represent medications prescribed by doctors to, in effect, “treat” the consequences of consuming wheat and grains. They prescribe drugs to treat the inflammation, swelling, skin rashes, gastrointestinal irritation, high blood sugars, airway allergy, and other abnormal effects all caused by wheat and grains.
The list includes anti-inf...
Source: Wheat Belly Blog - October 6, 2015 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle asthma cholesterol diabetes drugs gluten grains hypertension prescription medication reflux Source Type: blogs
Diuretic or Calcium Channel Blocker for CKD
It has been suggested by researchers that the diuretic clorthalidone should be the first line of antihypertensive therapy with a few caveats. Firstly in the presence of certain co-morbidities other drugs with a proven track record of reducing end organ damage should be instituted as first line instead. Thus it has been suggested that in patients with diabetic kidney disease and angiotensin receptor blocker (ARB) be commenced early due to its proven reno-protective effects in type 2 diabetics with kidney disease.
The results of the ACCOMPLISH trial as reported in the LANCET may change the above approach. From the available ...
Source: All Kidney News - September 29, 2015 Category: Urology & Nephrology Authors: jadhavbca Tags: Kidney News ACCOMPLISH Calcium Channel Blocker CKD DIOVAN Source Type: blogs
